ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jul 11, 2017
Loxo Oncology Presents Compelling Data on Its TRK Inhibitors
Image Source: Loxo Oncology. The field of oncology remains an area of intense focus with a dire need for new novel therapies. Loxo Oncology generated lots of excitement with the release of its clinical data for Larotrectinib, a TRK-inhibitor for the treatment of a diverse number of tumors.
Jul 10, 2017
Stock-Selection Methodology, the Valuentum Buying Index
Image Shown: The size of the circles generally reveals the relative emphasis we place on each investment consideration, while the arrows display the order of our process -- value first then technicals and momentum last.We outline the criteria behind the stock-selection methodology--the Valuentum Buying Index (VBI).
Jul 7, 2017
MLP Speak: A Critique of Distributable Cash Flow
Let’s talk about a controversial metric that is used in master limited partnership (MLP) reporting. Just how useful is it, and should it be allowed?
Jul 6, 2017
Walgreens Builds Out Its Network
Image Source: Mike Mozart. Walgreens continues its quest to build out its network of pharmacies. The goal is to maintain the largest network in the US, which would make exclusion from a payer’s network very difficult. Let’s review the recently-revised terms of the deal to acquire a portion of Rite Aid, the third-largest pharmacy chain in the US.
Jul 1, 2017
Malkiel Balks, Yellen Talks
Let’s first address how research in the financial industry is becoming more and more open to combining value and momentum considerations. We’ll also cover a few takeaways from the stress tests and some ‘strong’ talk from Fed Chair Janet Yellen.
Jun 30, 2017
The Biosimilar Revolution Remains Stymied
Image Source: Express ScriptsWe remain intrigued by the potential of the upcoming wave of biosimilar versions of well-established specialty drugs. Even though we have been disappointed by recent FDA decisions, we feel it is inevitable biosimilars will enter the market. Let’s update readers on our thoughts.
Jun 28, 2017
Incyte, Examining Epacadosat's Recent Data
Image shown: Incyte's stock price performance since the beginning of 2014.The need for innovative advances in oncology remains unmet in spite of the entrance of next-generation treatments. We will examine the recent data release from Incyte pertaining to its novel treatment Epacadosat. Incyte hopes it will boost response rates which will greatly expand the number of patients that can be effectively treated. Let’s examine the details of the data release.
Jun 26, 2017
Random Musings: Retail, REITs, BlackBerry, and More
Image shown: Best Buy's resiliency in the face of competition from Amazon. Let’s cover some recent news.
Jun 26, 2017
An Overview on Roche Holdings
Image Source: Roche. The healthcare industry remains a global enterprise with world-class companies working towards new treatments. Let’s have a look at the prospects of Roche Holdings.
Jun 19, 2017
Dividend Increases/Decreases for the Week Ending June 16
Let's take a look at companies that raised/lowered their dividends this week.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.